Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15.
Explore this paper's citation graph
Summary
Subgroup analysis of Checkmates 025 and the results of Checkmate 214 seem to indicate a better clinical outcome for immune therapy in metastatic RCC, and PD-L1 expression does not seems a reliable predictive marker of tumor response.
- Type
- letter
- Published
- 2018-04-27
- Cited by
- 3
- References
- 5
- OpenAlex
- https://openalex.org/W2800977437
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:14017459
Keywords
Medicine, Axitinib, Pembrolizumab, Oncology, Renal cell carcinoma
References
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma
- Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Cited by
- The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
- Role of TKI for Metastatic Osteogenic Sarcoma
- Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842–3
- Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Related papers
- Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
- Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
- EE652 Cost Effectiveness Analysis of Pembrolizumab for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
- Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience
- Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
- Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
- Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit